Compare MDIA & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDIA | LUCD |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 132.4M |
| IPO Year | N/A | 2021 |
| Metric | MDIA | LUCD |
|---|---|---|
| Price | $0.78 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 26.8K | ★ 720.5K |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $127,477,000.00 | $4,399,000.00 |
| Revenue This Year | N/A | $12.31 |
| Revenue Next Year | N/A | $152.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.96 | 5.01 |
| 52 Week Low | $0.73 | $0.75 |
| 52 Week High | $1.60 | $1.80 |
| Indicator | MDIA | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 28.12 | 61.67 |
| Support Level | $0.73 | $1.02 |
| Resistance Level | $1.00 | $1.16 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.60 | 100.00 |
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.